Considerations for Combinations Beyond Progression in Upper GI Cancer
Experts discuss how microsatellite-stable (MSS) status in this case affects the expected benefit of pembrolizumab and whether its continued use beyond progression in combination with other agents would be considered.
EP: 1.HER2- Upper GI Cancer
EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy
EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment
EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer
EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer
EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach
EP: 7.Megan’s Journey With HER2+ Upper GI Cancer
EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer
EP: 9.ADCs in HER2+ Gastric Cancer
EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer
Now Viewing
EP: 11.Considerations for Combinations Beyond Progression in Upper GI Cancer
EP: 12.Exploring Next-Line Options in HER2- MSS Gastric Cancer
Video content above is prompted by the following:
- How does the MSS status in this case affect the expected benefit of pembrolizumab, and would you consider its continued use beyond progression in combination with other agents?
Recent Videos
Related Content
